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Emicizumab is a recombinant, humanised bispecific monoclonal antibody that binds factor 
IXa and factor X. Although emicizumab mimics factor VIII, in that it enhances factor IXa-
mediated factor X activation, its mechanism of action is not exactly the same. For instance, 
factor VIII requires activation before it can interact with factor IXa, and due to its intrinsic 
instability, factor VIIIa loses rapidly its cofactor function. It thus has an on/off-switch. 
Emicizumab has no such on/off switch, and is immediately ready for action as soon as factor 
IXa is available. Secondly, factor VIIIa is the limiting factor within the tenase complex (it has 
the lowest concentration, and it inactivates rapidly), whereas due to the molar excess of 
emicizumab, factor IXa is the limiting component in emicizumab-supported factor Xa 
generation. Finally, FVIIIa stimulates factor IXa activity via a number of different 
mechanisms [1], whereas emicizumab predominantly promotes factor IXa and factor X to be 
in close proximity. It is not surprising therefore that emicizumab is less efficient as a cofactor 
compared to factor VIIIa. However, it is important to keep in mind that this does not mean 
that emicizumab is unable to facilitate the production of similar amounts of factor Xa. Less 
efficient implies that more factor IXa/Emicizumab complexes are needed to activate similar 
amounts of factor X as will the tenase complex. As long as enough factor IXa is available 
(produced by factor VIIa/tissue factor or factor XIa, or infused as part of clotting factor 
concentrates), then sufficient factor IXa/emicizumab complex can be formed. Although it is 
currently unclear how much factor IXa is generated in the different tissues following 
different types of injury, the significant reduction in annual bleed rate (ABR) points to 
sufficient amounts of factor IXa/emicizumab complex being generated to control 
spontaneous bleeds.  
Emicizumab is administered subcutaneously between once a week and once a month due to 
its half-life of almost a month. The HAVEN 1-4 research studies established its efficacy in 
haemophilia patients with and without inhibitors and granted licensure for use for bleeding 
prevention in Europe and North America as well as in an increasing number of other regions 
worldwide. At the registered emicizumab dose, patients achieve thrombin generation in the 
range of patients with mild haemophilia.  
In terms of efficacy, the results have been impressive in reducing the annual bleed rate 
especially in patients with alloantibodies to FVIII (inhibitors). In individuals with haemophilia 
A without inhibitors, the efficacy is similar to that of well-controlled prophylaxis with the 
advantage of subcutaneous once weekly or less frequent dosing rather than intravenous 
injection two to three times a week. The issues of what level of physical activity can be 
safely performed and how to manage the peri-surgical risk of bleeding remain to be defined. 
In terms of safety, the most common adverse events are injection site skin reactions, which 
have been reported in up to 15% of patients [2]. These are usually mild and self-limiting with 
most patients continuing on the emicizumab despite these reactions. 
More important however are the episodes of thrombosis, thrombotic microangiopathy 
(TMA) and death, which will be discussed in this commentary. The first reports of 
thrombotic complications came from the HAVEN 1 trial where three patients developed 
TMA, two developed thrombosis and one patient died [2].  
 
Thrombotic microangiopathy 
 3 
TMA is a very rare, life-threatening condition and in the form of thrombotic 
thrombocytopenic purpura (TTP) it is associated with congenital or acquired deficiency of 
ADAMTS 13. The incidence of TTP in the general population is approximately 10 in a million 
per year [3]. TMA has rarely been observed in haemophilia patients undergoing factor 
replacement therapy [4]. Thus, the development of this complication in 3 of 109 patients in 
the HAVEN 1 trial was immediately perceived as unlikely to be a chance occurrence. All the 
affected patients developed thrombocytopenia, and displayed laboratory markers of 
haemolysis and fragmented red cells on the peripheral blood film while maintaining normal 
ADAMTS13 levels, configuring the picture of atypical TTP. A detailed analysis of the TMA 
cases showed that they were all exposed to FEIBA at doses of over 100units per Kg per day, 
given to treat acute bleeding episodes during emicizumab prophylaxis. In contrast, no 
episodes were observed when rFVIIa was used to treat the acute bleeding episodes. In 
explaining the difference between FEIBA and rFVIIa in triggering TMA in patients on 
emicizumab, it is worth noting that FEIBA contains factors IX/IXa as well as X/Xa, which are 
the substrates for the bispecific antibody. Since Emicizumab does not require activation to 
exert its cofactor function, an excess of factor IXa may lead to uncontrolled thrombin 
generation and the resulting thrombotic complications. Only very limited information is 
available on the episodes of thrombosis that occurred outside HAVEN 1 [5]. One further 
episode of TMA has been reported in the post marketing setting [5]. In contrast to the 
clinical course of classical TTP, the microangiopathy in these individuals resolved rapidly 
following discontinuation of the FEIBA treatment. In at least one of the cases, it was possible 
to resume emicizumab and treat bleeds with rFVIIa without recurrence of the TMA. 
 
Venous and arterial thrombosis 
Seven thrombotic events have been reported of which three were venous, one was arterial 
while the locations of the remaining three events have not been reported. Two of the 
venous thromboses were reported in HAVEN 1. One was a right saphenous vein thrombosis 
after two doses of FEIBA to treat joint and right shin bleeds on consecutive days; the patient 
applied an ice pack to the shin bleed and developed extensive skin necrosis over the area. 
Another patient developed cavernous sinus thrombosis after receiving FEIBA to treat a joint 
bleed. Both of these patients with thrombosis received concomitant treatment with FEIBA 
at a dose of >100u/kg/day. After resolution of the cavernous sinus thrombosis the patient 
restarted emicizumab with no further problems and uneventfully received rFVIIa to treat 
joint bleeds and a dental procedure [2].  
 
Deaths 
A total of 10 deaths have been reported so far in patients on emicizumab. Clinicians who 
cared for 2 of the patients in the compassionate use program reported that those deaths 
were unrelated to the emicizumab.  The haemophilia A patient with an inhibitor in the 
HAVEN 1 trial died from rectal bleeding; he refused a blood transfusion and the death was 
considered to be unrelated to the drug. A point for consideration however, is that the use of 
emicizumab limits the use of other treatments such as FEIBA. It cannot be excluded that 
under such conditions, the use of emicizumab prevents the application of FEIBA, which 
could be used to control bleeding. 
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We have insufficient information on the other seven deaths to judge whether or not 
emicizumab could have played a role.  Whilst we understand the need to protect privacy, 
we feel that the current listing of the deaths at www.emicizumabinfo.com [5] without 
details about the causes or at least circumstances is of suboptimal utility, and we 
recommend the manufacturer to explore options to expand the information provided to 
include, as a minimum, the cause of death and the patient ?ƐŝŶŚŝďŝƚŽƌƐƚĂƚƵƐ.  
The manufacturer states that there are currently 2500 haemophilia A patients with and 
without inhibitors being treated with emicizumab. This would give a raw mortality rate of 
4/1000 treated patients. We cannot judge whether this is the expected rate, or is higher/ 
lower than expected, as we do not have the critical information needed for a proper 
appraisal. Indeed, we do not know the demographics of the patients and the length of 
exposure to emicizumab, as well as the  “ĐŽŶƚƌŽů ?mortality rate in patients treated with 
bypassing agents or factor concentrates but without emicizumab.  
As the number of emicizumab users increases, it is likely that the number of deaths will 
increase. It is difficult to predict if more or less of them will be reported, but the quest of the 
community to find out whether or not there is an excess of deaths on emicizumab is unlikely 
to fade away. Therefore, we suggest the manufacturer establishes an independent panel to 
examine the drug-relatedness of all the adverse events, including deaths, and to set up 
studies that will help to generate the evidence needed to answer this question.  
 
Acquired haemophilia 
Emicizumab is only licensed for patients with congenital haemophilia A with and without 
inhibitors. The efficacy and relative safety of emicizumab in the HAVEN 1, 2 and 4 trials led 
some clinicians to start using it off license in patients with acquired haemophilia despite the 
lack of published efficacy and safety data. The dose and frequency used have been the same 
as those licensed for congenital haemophilia and inhibitors. We expect the number of 
patients with acquired haemophilia who have been exposed to emicizumab to be very small, 
but despite this, one patient developed pulmonary emboli, one had a thrombotic stroke and 
a third patient died suddenly (Table 1). Even against the relatively high death rate in 
acquired haemophilia in general [6], three deaths in a very small series of treated cases is an 
alarming figure. The safety profile of this drug in acquired haemophilia remains to be 
established, and patients should not be exposed to emicizumab for this indication outside 
clinical trials. There are good reasons for the thrombotic risk being higher in this group, as 
older age, autoimmunity, and cancer, which are risk factors for acquired haemophilia, are 
also risk factors for thrombosis. Furthermore, patients with severe haemophilia produce no 
or very little FVIII, whilst acquired haemophilia patients produce large amounts of FVIII 
which is initially neutralised by the autoantibody but later, as the immunosuppression kicks 
in, becomes available in the circulation and often reaches supra normal levels. These 
features suggest that if this drug is used in clinical trials in patients with acquired 
haemophilia, the dose may need to be lower and more closely monitored so that the 
treatment is stopped as the endogenous FVIII starts to rise. 
 
The use of concomitant rFVIIa 
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In the current issue of the Journal of Thrombosis and Haemostasis, Levy and colleagues 
present the data on bleeds in patients on emicizumab that were treated with rFVIIa in the 
Haven 1, 2 and 4 clinical trials [7]. A total of 61 patients with congenital haemophilia A and 
inhibitors were treated for a total of 210 bleeds with rFVIIa. No thromboses or TMAs were 
observed in these patients. It should be noted, however, that patients with a high risk of 
thrombosis were excluded from entering these trials in the first place and not many of the 
rFVIIa treatments were used in the settings of sepsis, surgery or major trauma. 
Furthermore, around half of the rFVIIa exposures were single dose treatments. 
 
Monitoring of adverse events 
Adverse event monitoring is an essential component of studies in all phases of development 
of new drugs and observed cases are included in trial publications. Adverse events should 
also be reported to national systems available for reporting events on any medication, as 
well as to multicenter/multinational databases such as the European EUHASS, Canadian BDR 
and US ATHEN haemophilia specific systems. In our view clinicians should also be permitted 
to openly report adverse events in clinical trial patients once a drug has been licensed. 
Currently confidentiality agreements in clinical trial contracts prevent clinicians from 
reporting adverse events to independent adverse event databases. Whilst it is reasonable 
not to disclose events during phase III randomized double-blind clinical trials, which are 
overseen by dedicated drug safety monitoring boards (DSMB), open reporting and 
disclosure should be adopted for licensed drugs in post-marketing trials, particularly when 
drugs are prescribed as part of usual care after licensure.  
 
In the case of emicizumab, a website [5] presenting the cumulative adverse event data 
reported to all sources has been made available as an open access resource to US physicians 
by Genentech (part of Roche, the manufacturer of emicizumab). The site is updated every 
three months and contains data from throughout the world, but unfortunately it has not 
been open to other regions of the world. Another issue with the website is that, while it 
clearly displays the cumulative data, details of the specific events, especially in the case of 
deaths, are limited. This, in turn, makes it difficult to impossible to independently assess the 
likelihood of a causal link between emicizumab administration and the reported adverse 
event. With regard to causality assessment, because emicizumab has a long half-life, 
adverse events up to 3 months after discontinuation of the drug should be reported. This is 
of particular importance when emicizumab is temporarily discontinued in the setting of 
elective major surgery in inhibitor patients where full dose FEIBA may be used to cover the 
surgery. Finally, contextual reporting of the cumulative population exposure to emicizumab 
(at least in terms of estimated treatment years) should be posted to provide a denominator 
to the events. 
 
Conclusion 
Emicizumab has shown marked efficacy and relative safety in clinical trials and is now 
licensed in Europe and North America. The thrombotic events in the trials occurred when 
patients also received FEIBA at a dose greater than 100u/kg/day. Although the data suggest 
that rFVIIa is safer than FEIBA when used in patients on emicizumab, more data on its use 
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especially in the context of sepsis, surgery and major trauma are required. It is not known if 
the deaths of ten patients taking emicizumab represent a higher than expected death rate, 
and prospective observational studies should be set up to answer this question. In the 
meantime, all adverse events but particularly TMA, thrombosis and deaths of patients 
taking or having recently discontinued emicizumab should be reported to the relevant 
authorities and databases. 
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Source Patients Age 
yrs 
Venous 
thrombosis 
Arterial 
thrombosis 
Total 
thrombosis 
Thrombotic 
microangiopathy 
Deaths Death details 
HAVEN 1 [1] 109 (inhibitor) >12 2 0 2 3 1 TMA +bleeding 
HAVEN 2 [8] 88 (inhibitor) <12 0 0 0 0 0  
HAVEN 3 [9] 152 (non-
inhibitor) 
>12 0 0 0 0 0  
HAVEN 4 [10] 48 with or 
without inhibitor 
>12 0 0 0 0 0  
HOHOEMI [11] 13 (inhibitor) <12 0 0 0 0 0 0 
STACEY (f) [5,12] 195 (inhibitor) >12 1 1 0 1  
Compassionate 
use [5] 
Not disclosed  
Any 
0 0 0 0 3 Sepsis, 
Cerebral bleed, 
Pseudotumour bleed 
  
Expanded access 
[5] 
Not disclosed Any 0 0 0 0 1  
Post-marketing 
[5] 
Unknown Any 2 2 1 3  
Post-marketing 
acquired 
haemophilia [5, 
13,14] 
Unknown Any 1 1 2 0 1 Sudden death 
Total [5] 2500    7 4 10  
 
Compassionate use is the availability of the unlicensed drug to individuals assessed on a case by case basis provided certain criteria (such as no satisfactory 
approved alternative) are met. Expanded access is the availability of the drug to intermediate and large numbers prior to approval [5].  
 
